The Valuation Re-Frame: From Consumer Diet Drug to Sovereign Infrastructure Behind closed doors in institutional roundtables and private family office briefings, a fundamental valuation shift has occurred. The early narrative—dominated by direct-to-consumer weight-loss telehealth, consumer hype, and simple scale metrics—has run its course. Institutional allocators are now evaluating incretin receptor agonists through a far more rigorous lens: multi-systemic geroprotective pl